Nanologica will participate at Redeye Growth Day 2023 on June 1st. CEO Andreas Bhagwani will present at 11.35. The In Focus interview is live broadcasted at https://www.redeye.se/events/871323/redeye-growth-day
In order to create the best conditions for success in preparative chromatography, the company’s operations are focused on Chromatography and the Drug Development operations are down-prioritized and placed in subsidiaries for future opportunities. The management team is adapted to reflect this and CSO Gary Pitcairn and VP Drug Development Ulf Ericsson will leave the company for new opportunities. “ Our work within Drug Development has reached a point where continued development is very resource-intensive and we
After successfully implementing fine-tuning in production, Nanologica’s product now meets the company’s own requirements for quality in all evaluated parameters. The company is therefore continuing to formally approve products to be able delivery to customers progressively. ”After making further fine-tunings in one of the production steps, we now have a product that we are satisfied with and that we can proudly deliver to customers. Finally! This means that we now can move on with the
Fine-tuning production The company’s absolute top priority in the beginning of the year has continued to be production. We have implemented fine-tunings in one of the process steps and evaluation of these is ongoing. We remain committed to ensuring that our product within preparative chromatography, NLAB Saga®, maintains the highest quality over time, and we will not deliver to customers until we are completely satisfied with the product. Even though it is taking more time
Closer to a commercial break-through In 2022, Nanologica has taken several steps forward – we launched our product in preparative chromatography, took our first orders for this product and listed the company on Nasdaq Main Market. We did not reach the goal of delivering products, but have gradually come closer. We are committed to achieving a commercial breakthrough in 2023. 2022 has been characterized by an unstable situation in the world and great uncertainties in
